Mr. Hugh MacNaught reports

VENTRIPOINT DIAGNOSTICS ANNOUNCES SUPPORT FOR THE GLOBAL CONGENITAL HEART DISEASE ALLIANCE

Ventripoint Diagnostics Ltd. has expressed its support for the Global Congenital Heart Disease Alliance (GCHDA), a newly forming industry alliance dedicated to accelerating the development, commercialization and global adoption of congenital cardiovascular technologies.

GCHDA brings together industry partners, clinicians, researchers, regulators, investors and patient communities to address the unique challenges facing innovators in congenital heart disease (CHD) -- the most common birth defect in the world. Through membership and advocacy programs, multicentre research collaboration, and a convening platform of summits and innovation showcases, GCHDA aims to build a unified support ecosystem for a field that has long been fragmented.

The announcement comes on the heels of the World Heart Federation's World Heart Report 2026, which found that CHD now affects approximately 2 per cent of live births globally and that the number of people living with CHD worldwide has grown to an estimated 16 million -- up from 11.8 million three decades ago. The report also found that more than 90 per cent of children in lower- and middle-income countries lack timely access to CHD care, underscoring the urgent need for the kind of cross-sector collaboration GCHDA is designed to enable.

"Congenital heart disease affects patients across every stage of life, from infancy through adulthood, and the technologies needed to diagnose and monitor these conditions require exactly the kind of collaborative ecosystem that GCHDA is working to build," said Joe Hostetter, director of the CHD program at Ventripoint Diagnostics. "With the growing CHD population and so many patients in underserved regions lacking access to timely care, we believe accurate, accessible imaging has to be part of the solution. Supporting GCHDA reflects our commitment to working alongside the broader CHD community to help close that gap."

Ventripoint's flagship platform, VMS+, uses AI to transform standard 2-D echocardiograms into highly accurate 3-D models of all four heart chambers, bringing cMRI-level measurement accuracy to the point of care -- including for patients with congenital heart conditions, where complex anatomy often makes traditional imaging difficult. By supporting GCHDA, Ventripoint aims to help connect its imaging technology with the clinicians, researchers and patient communities working to improve outcomes for people living with CHD worldwide.

"We are pleased to welcome Ventripoint as a supporter of the Global Congenital Heart Disease Alliance," said Julia Friesen, executive director, Global Congenital Heart Disease Alliance. "We exist to bring focused attention and determined project execution to the congenital heart disease community, leveraging our resources and relationships across finance, hospitals, insurance and the scientific community. As part of our initial efforts, we will assist in funding and placing four VMS+ cardiac imaging units to directly support the CHD community and expand access to advanced diagnostic care. With Ventripoint as a partner, we look forward to helping patients, families, hospitals, and research teams gain access to the technologies and resources needed to improve care and advance innovation globally."

Ventripoint plans to participate in GCHDA's programming, including its annual summit and innovation showcases, and looks forward to collaborating with fellow members of the alliance on shared research and commercial initiatives that advance care for the CHD community.

About Ventripoint Diagnostics Ltd.

Ventripoint Diagnostics is dedicated to improving diagnostic imaging through tools that offer higher performance, lower cost, faster turnaround and greater patient comfort. Its flagship product, VMS+, enhances standard echocardiography to deliver cMRI-level accuracy for volumetric measurements and ejection fractions across all four chambers of the heart, supporting applications including congenital heart disease, pulmonary hypertension and cardiotoxicity monitoring in oncology patients.

We seek Safe Harbor.